Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Oct 5, 2011

Premium

Synthetic Genomics Vaccines, which focuses on developing vaccines using sequencing and synthetic genomic technologies, has appointed Sammy Farah as president.

Farah joins the company from Immune Design, where he was chief business officer. Previously, he was at Versant Ventures, where he specialized in biotechnology investing; and at Merck, where he led technology support for multiple commercial vaccines.

He holds an MBA from the Wharton School at University of Pennsylvania, a PhD in biochemical engineering from Stanford University, and a BS in biochemical engineering from MIT.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more